Overview
Design Therapeutics Q2 net loss of $19.1 mln misses analyst expectations
Favorable PK data for DT-216P2 in Friedreich Ataxia; U.S. trials on hold
Outlook
Company plans to address FDA clinical hold with clinical data
Result Drivers
FDA HOLD - U.S. trials for DT-216P2 are on hold due to FDA concerns about starting dose, with plans to address using clinical and nonclinical data
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income | Miss | -$19.08 mln | -$18.90 mln (3 Analysts) |
Q2 Basic EPS | -$0.34 | ||
Q2 Operating Expenses | $21.57 mln | ||
Q2 Operating Income | -$21.57 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Design Therapeutics Inc is $5.00, about 13% above its August 6 closing price of $4.35
Press Release: ID:nGNX17c95l
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.